Next-Generation Immunotherapies
In vivo CAR T and the Next Wave of Immune Reprogramming
5/13/2027 - May 14, 2027 ALL TIMES EDT
The ability to engineer therapeutic immune cells directly inside the body could transform how advanced immunotherapies are developed, manufactured, and delivered. With in vivo CAR T now generating early patient data and record investment from big pharma, Cambridge Healthtech Institute’s 6th Annual Next-Generation Immunotherapies conference will explore the technologies and translational strategies driving the field forward. The program will cover viral vectors, nanoparticles, mRNA, fusogens, and virus-like particles designed to target T cells, NK cells, myeloid cells, and hematopoietic stem cells. Key discussions will address biodistribution, transduction efficiency, genome integration, payload design, immune responses, cellular persistence, safety controls, and mitigation of CRS, neurotoxicity, and off target activity. Additional topics include CAR binder engineering, AI-assisted discovery, and in vivo expression of antibodies, T cell engagers, and multiple payloads.